5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

STERILISATION OF S-NITROSOTHIOLS

This invention provides a method of sterilising an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.

Chemical Compounds

Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted ...

5-hydroxysapogenin derivatives with anti-dementia activity

The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed ...

TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Sapogenin derivatives and their use in the treatment of cognitive dysfunction

The invention discloses the use of sapogenin derivatives in the treatment of cognitive dysfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed.

Sapogenin derivatives and their use in the treatment of cognitive dysfunction

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed ...

Unit serving appetite suppressant compositions with steroidal glycosides

An inherently nourishing edible appetite suppressant unit serving product comprising a steroidal glycoside, preferably obtainable from Hoodia plants, in a defined proportion to the total energy content. A method of lowering daily calorie (daily energy) intake is also disclosed.

STERILISATION OF S-NITROSOTHIOLS

This invention provides a method of sterilising an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use. 1. Sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol , wherein the S-nitrosothiol is in dry solid form.2. Sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol as claimed in claim 1 , wherein the sterile S-nitrosothiol or the sterile pharmaceutical pre-composition comprising S-nitrosothiol is in a dry sterile environment in a sealed container.3. Sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol as claimed in claim 2 , wherein the seal is arranged so that the container can be opened claim 2 , for example pierced claim 2 , under sterile conditions to allow the sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol to be formulated with other desired ingredients to make a final pharmaceutical composition for administration.4. Sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol as claimed in claim 2 , wherein the seal is arranged so that a sterile liquid can be introduced into the container claim 2 , for example using a syringe provided with a hollow needle claim 2 , to dissolve or suspend the sterile dry solid S-nitrosothiol or the sterile pharmaceutical pre-composition in situ within the container.5. Sterile S-nitrosothiol or a sterile pharmaceutical pre-composition ...

5-Hydroxysapogenin derivatives with anti-dementia activity

The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed ...

Therapeutic methods and uses of sapogenins and their derivatives

The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.

5-hydroxysapogenin derivatives with anti-dementia activity

The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

Sterilisation of S-nitrosothiols

This invention provides a method of sterilizing an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.

Sapogenin derivatives, their synthesis and use, and methods based upon their use

The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the absence of cognitive, neural and neuromuscular impairment. Methods of synthesis, treatment and pharmaceutical compositions are also disclosed.

Substituted sapogenins and their use

The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed ...

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed

Nitric oxide synthase inhibitors

The present invention relates to novel amidino compound of formula (I). to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.

Substituted sapogenins and their use

The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed

SUBSTITUTED SAPOGENINS AND THEIR USE

The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed ...

Nitric oxide synthase inhibitors

The present invention relates to novel amidino compound of formula (I). to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.

Sterilisation of s-nitrosothiols

This invention provides a method of sterilising an S-nitrosothiol, for example S- nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.

5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Treatment of neurotrophic factor mediated disorders

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self- regulated homeostasis of neurotrophic factors(NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non- toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF- mediated disorders, particularly neurological, psychiatric, inflammatory,allergic,immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Sterilisation of s-nitrosothiols

This invention provides a method of sterilising an S-nitrosothiol, for example S- nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.

5-hydroxysapogenin derivatives with anti-dementia activity

The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

Nitric oxide synthase inhibitors

Sapogenin derivatives, their synthesis and use, and methods based upon their use

The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the absence of cognitive, neural and neuromuscular impairment. Methods of synthesis, treatment and pharmaceutical compositions are also disclosed.

Inhibitors of nitrogen oxide synthase

Substituted sapogenins and their use

The invention discloses substituted sapogenins and their use in the treatmen t of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

Substituted sapogenins and their use

The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

Dioxo-alkanes and dioxo-alkenes

Compounds of general formula (I) wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted -CO-(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted -CO-(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted -CO-(C2-10alkenyl), optionally substituted aryl, and optionally substituted -CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n- where n = 0, 1 or 2, optionally substituted aryl-S(O)n- where n = 0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1 = R2 = hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically ...

Sapogenin derivatives and their use in the treatment of cognitive dysfunction

The invention provides novel compounds of general formulae (I) and (II) as defined, their stereoisomers and racemic mixtures, their pharmaceutically acceptable pro-drugs and salts, which are useful in the treatment of cognitive dysfunction and similar conditions.

Substituted sapogenins and their use

The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.

Sapogenin derivatives, their synthesis and use

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Nitric oxide synthase inhibitors

The present invention relates to novel amidino compounds of formula (I), to a process for their manu-facture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as se-lective inhibitors of inducible nitric oxide synthase.

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

Det er beskrevet anvendelse av sapogeninderivater ved behandling av kognitiv disfunksjon og lignende tilstander. Fremgangsmåter for behandling samt farmasøytiske sammensetninger er også beskrevet. The use of sapogenin derivatives in the treatment of cognitive dysfunction and similar conditions has been described. Methods of treatment as well as pharmaceutical compositions are also described.

Amidino compounds, preparation method thereof, pharmaceutical composition them containing, their use and an intermediate

The present invention relates to novel amidino compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.

COMPOUNDS DERIVED FROM DIOXOALCANS AND DIOXOALKENS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT ASTHMA, TOS, PURITO, HYPERSENSITIVITY.

Sapogenin derivate zur behandlung von kognitiven störungen

Therapeutische verwendung von sapogeninen

Substituierte sapogenine und ihre verwendung

Theraputic methods and uses of sapogenins and their derivatives

Sapogenin derivate, deren synthese und verwendung

5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia

THE INVENTION DISCLOSES THE USE OF SAPOGENIN DERIVATIVES IN THE TREATMENT OF CONGNITIVE DISFUNCTION AND SIMILAR CONDITIONS. METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION ARE ALSO DISCLOSED.

Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας

Η εφεύρεση γνωστοποιεί τη χρήση παραγώγων σαπωγενινών στην αντιμετώπιση διανοητικής δυσλειτουργίας και παρεμφερών καταστάσεων. Μέθοδοι αντιμετώπισης και φαρμακευτική σύνθεση γνωστοποιούνται επίσης.

5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz

5-hydroxysapogenin derivate mit aktivität gegen demenz

Therapeutic methods and uses of sapogenins and their derivatives

Theraputic methods and uses of sapogenins and their derivatives

Therapeutic methods and uses of sapogenins and the

Theraputic methods and uses of sapogenins and their derivatives

Portable sanitisation device for sanitising flexible face masks

A portable sanitisation device (10) for sanitising flexible face masks by ultraviolet light irradiation, comprises an openable and closable housing (11), which when closed encloses a treatment chamber with a target irradiation zone to accommodate in a predetermined position therein a flexible face mask in a given generally concavo-convex wear configuration, and ultraviolet light radiation means arranged in the housing to direct ultraviolet light towards the target irradiation zone for irradiation of a face mask when in the zone. The radiation means comprises two opposing pluralities of mutually spaced-apart and three-dimensionally distributed ultraviolet-light-emitting diodes (19, 20) oriented to direct emitted ultraviolet light into the target irradiation zone from multiple directions in three-dimensions for incidence in the case of one plurality (19) on the concave side and in the case of the other plurality (20) on the convex side of a notional three-dimensional region corresponding with the given wear configuration of a face mask when in the predetermined position in the zone. The housing (11) when closed provides a sealed enclosure confining emitted ultraviolet light to the interior of the housing.

Anvendelse av sapogeniner samt derav ved fremstilling av medikamenter

Det beskrives terapeutiske fremgangsmåter og anvendelser av visse steroidale sapogeniner, beslektede forbindelser og derivater derav, ved behandling av ikke-kognitiv nevrodegenerering, ikke-kognitiv nevromuskulær degenerering, motor-sensorisk nevrodegenerering eller reseptor dysfunksjon eller tap i fravær av kognitiv, nevral og nevromuskulær forringelse.

Metodo y usos terapeuticos de sapogeninas y sus derivados

1.- Uso de uno o más agentes activos seleccionados de:A. compuestos de la Fórmula I: caracterizado porque en la fórmula general (I):R1, R2, R3, R4, R5, R6, R7, R8, R10, R13, R18, R19, R20, R21, R22, R23, R24, R26, R27, R28, R29, R30, R31, R32, son independientemente H, OH, =O, átomo halo, (Me-S-), (Me-SO-), (Me-SOr), N3-, NH2-, MeSO2NH-, alquilo o ausente u OR donde R = grupo alquilo o acilo;-R9, R11, R12, R14, R15, R16, R17, R25, R33, pueden ser un H, OH, átomo halo, (Me-S-), (Me-SO-), (Me-SO2-), N3-, NH2- MeSO2NH-, alquilo o ausente u OR donde R = grupo alquilo o acilo;..... representa un enlace doble opcional;caracterizado porque además de lo anteriorR33 o R14 = grupo alquilo;A. Compuestos de la Fórmula II: caracterizado porque en la fórmula general (II):-R1, R2, R3, R4, R5, R6, R7, R8, R10, R13, R18, R19, R20, R21, R22, R23, R24, R26, R27, R28, R29, R30, R31, R32, R34, son independientemente H, OH, =O, átomo halo, (Me-S-), (Me-SO-), (Me-SO2-), N3, NH2-, MeSO2NH-, alquilo, OR dondeR = grupo alquilo o acilo o ausente;R9, R11, R12, R14, R15, R16, R17, R25, R33, R35, pueden ser un H, OH, átomo halo, (Me-S-), (Me-SO-), (Me-SO2-) , N3-, NH2-, ...

Sapogenin derivate, deren synthese und verwendung

Portable sanitisation device for sanitising flexible face masks

A portable sanitisation device 10 for sanitising flexible face masks by ultraviolet light irradiation, comprises an openable and closable housing 11, which when closed encloses a treatment chamber with a target irradiation zone to accommodate in a predetermined position therein a flexible face mask in a given generally concavo-convex wear configuration. There is a UV light radiation means arranged in the housing to direct UV light towards the target irradiation zone, wherein the radiation means comprises two opposing pluralities of mutually spaced-apart UV light-emitting diodes 19, 20 oriented to direct emitted UV light into the target irradiation zone from multiple directions. One plurality of UV LEDs 19 are on the concave side and the other plurality of UV LEDs 20 are on the convex side of a notional three-dimensional region corresponding with the given wear configuration of a face mask when in the predetermined position in the zone. The housing 11 when closed provides a sealed enclosure confining emitted ultraviolet light to the interior of the housing. There is also a method of sanitising a flexible face mask with the device wherein the UV light sources 19, 20 are activated for a time sufficient to sanitise the mask.

Hemmstoffe der stickstoffmonoxid-synthase

Therapeutische verwendung von sapogeninen